Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity“Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).”
Semaglutide in Adults with Type 1 Diabetes and Obesity“Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.”
{
"schema":"https://miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"semaglutide",
"title":"semaglutide",
"kind":"standard",
"summary":"Evidence is being populated by Grok web",
"created":"2026-06-29T17:01:15.697Z",
"body": [
"## Overview\nEvidence is being populated by Grok web search."
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-06-29T17:01:16.648Z",
"register":"standard",
"category":null
},
"sources": [
{
"id":"s1",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40934115/",
"title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity",
"quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).",
"summary":"71-week RCT: -13.6% weight loss with 25 mg oral sema vs -2.2% placebo; more GI AEs.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:01:15.855Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"genesis",
"hash":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12",
"quote_sha256":"0d1a7ed9734b3e3958ba6d9f10a489a98de952adae53a35b3248fd82d6e8a568"
},
{
"id":"s2",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40961952/",
"title":"Once-weekly semaglutide 7·2 mg in adults with obesity",
"quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.",
"summary":"Phase 3 trial of higher-dose semaglutide 7.2 mg for obesity.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:01:15.855Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12",
"hash":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22",
"quote_sha256":"dd0a7a4d830e8953b254e1ce8a10063e80575dddf26aaf92d45b3f3ac829bcb6"
},
{
"id":"s3",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40550013/",
"title":"Semaglutide in Adults with Type 1 Diabetes and Obesity",
"quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.",
"summary":"RCT evaluating semaglutide in T1D + obesity.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:01:15.855Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22",
"hash":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa",
"quote_sha256":"cfabad54ee1f8aa4df5700f1bf916f4a926ea6fc634ff6679b7aab4a4b263f82"
},
{
"id":"s4",
"type":"review",
"url":"https://pubmed.ncbi.nlm.nih.gov/40620322/",
"title":"The expanding role of semaglutide: beyond glycemic control",
"quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.",
"summary":"2025 review on semaglutide's expanding indications (NAFLD, HF, PCOS, etc.).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:01:15.855Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa",
"hash":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87",
"quote_sha256":"5488b614069df44d07e9a919f15a614583ff94929bb586e480d9ec83443af774"
},
{
"id":"s5",
"type":"clinical_trial",
"url":"https://clinicaltrials.gov/study/NCT07046273",
"title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide",
"quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...",
"summary":"New Phase III trial registration for semaglutide (Jul 2025).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:01:15.855Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87",
"hash":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506",
"quote_sha256":"4e58cc6ce72cecb985170bb827fd2cafc9c3616328162a3ff81e6d7df1fd8230"
}
],
"type":"article",
"updated":"2026-10-08T11:49:46.253Z",
"version":1,
"hash":"f5a5a57533c5d5f11c36ac853524eb7d77cb047a20961f1693e7050dd6228567",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH https://miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"https://miscsubjects.com/a/semaglutide",
"json":"https://miscsubjects.com/a/semaglutide.json",
"markdown":"https://miscsubjects.com/a/semaglutide.md",
"theme":"https://miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/semaglutide",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/semaglutide.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/semaglutide.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/semaglutide",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/semaglutide/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/semaglutide/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"https://miscsubjects.com/api/jarticles/semaglutide",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"https://miscsubjects.com/api/jarticles/semaglutide",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"semaglutide",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/semaglutide/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"semaglutide"
}
}
]
}